# Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

> **NCT00616967** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 68 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** paclitaxel albumin-stabilized nanoparticle formulation
- **DRUG:** vorinostat
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00616967
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2008-05
- **Primary completion:** 2014-06
- **Final completion:** 2027-02
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616967, "Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00616967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*